Treatment of idiopathic neutropenia in the elderly with recombinant human granulocyte colony-stimulating factor.
We administered recombinant human granulocyte colony-stimulating factor (rhG-CSF) intravenously for 2 weeks to 2 elderly patients with severe neutropenia. The absolute neutrophil count (ANC) recovered promptly after the initiation of rhG-CSF therapy and reached a peak (greater than 10 x 10(9)/l) on the 13th day. The ANC fell rapidly after rhG-CSF was discontinued, but it remained within the normal range after therapy. There were no side effects during the entire course of treatment. Therefore, rhG-CSF seems to be a most beneficial treatment in elderly patients with severe neutropenia.
Sonoda
Y
Y
Department of Hygiene, Kyoto Prefectural University of Medicine, Japan.
Yashige
H
H
Fujii
H
H
Maekawa
T
T
Abe
T
T
D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D001772:Blood Cell Count / Q000187:drug effects; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D003114:Colony-Forming Units Assay; D004341:Drug Evaluation; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D006801:Humans; D007262:Infusions, Intravenous; D009503:Neutropenia / Q000097:blood / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D013997:Time Factors
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor